DC-CIK细胞治疗晚期转移性鼻咽癌的疗效

发布时间：2018-01-26 07:22

本文关键词： 树突状细胞细胞因子诱导的杀伤细胞转移性鼻咽癌细胞免疫治疗　出处：《中国肿瘤生物治疗杂志》2017年01期 　论文类型：期刊论文

【摘要】：目的:评价DC-CIK细胞治疗晚期转移性鼻咽癌患者的疗效。方法:回顾性分析2011年8月至2015年6月解放军第八一医院肿瘤生物治疗科行DC-CIK细胞治疗的29例晚期转移性鼻咽癌患者。观察DC-CIK细胞治疗前后患者的疗效、安全性及EB病毒VCA-IgA抗体水平和淋巴细胞亚群的变化。结果:29例鼻咽癌患者经DC-CIK细胞治疗后客观缓解率为0,疾病控制率为65.5%,中位生存时间为42个月,1~4年生存率都为68.0%,无严重不良反应。治疗后29例患者的外周血EB病毒VCA-IgA抗体显著低于治疗前[(30.88±3.91)U/ml vs(49.86±5.02)U/ml,P0.05)]。经细胞治疗后CD8~+T细胞显著上升(P0.05)、CD4~+/CD8~+T细胞比值显著下降(P0.05)。结论:DC-CIK细胞治疗转移性鼻咽癌安全、可行,能产生一定的临床获益。
[Abstract]:Objective: to evaluate the efficacy of DC-CIK cells in the treatment of advanced metastatic nasopharyngeal carcinoma (NPC). From August 2011 to June 2015, 29 patients with advanced metastatic nasopharyngeal carcinoma (NPC) treated by DC-CIK cell therapy in the department of tumor biotherapy, 81th Hospital of PLA were retrospectively analyzed. The fine DC-CIK was observed. The curative effect of patients before and after cell therapy. Results the objective remission rate of 29 patients with nasopharyngeal carcinoma after DC-CIK cell therapy was 0. The disease control rate was 65.5, the median survival time was 42 months and the 1-4 year survival rate was 68.0%. There was no serious adverse reaction. The antibody of EBV VCA-IgA in peripheral blood of 29 patients after treatment was significantly lower than that before treatment. [After cell therapy, CD8T cells increased significantly (P0.05). The ratio of CD4 ~ / CD8T cells decreased significantly (P 0.05). Conclusion: it is safe and feasible to treat metastatic nasopharyngeal carcinoma with w DC-CIK cells, and can produce some clinical benefits.
【作者单位】：解放军第八一医院肿瘤生物治疗科;南京中医药大学药学院;
【基金】：南京军区医学科技创新资助项目(No.14MS052)~~
【分类号】：R739.63
【正文快照】： 鼻咽癌是发生于鼻咽部黏膜处的常见恶性肿瘤,其发病带有明显的地域及性别特征[1]。由于其解剖部位较深、解剖结构复杂,早期鼻咽癌不易被发现,约有70%的患者在确诊时已经为晚期[2]。早期鼻咽癌首选放射治疗,晚期鼻咽癌主要采用放化疗结合的治疗方法[3]。虽然传统的治疗方法取得

【相似文献】